tial dose of these drugs at the start or during the treatment of sitagliptin were excluded because the change of these drugs could largely affect the results of HbA1c and make the interpretation of sitagliptin's effects complicated. In results, 164 type 2 diabetic patients (93 males and 71 females) were enrolled in the present study (Table 1 ). This study was conducted according to the principles expressed in the Declaration of Helsinki. Informed consent was obtained from each subject after full explanation of the purpose, nature, and risk of all procedures used. The protocol was approved by the ethical review committee at Kurume University School of Medicine.
Sitagliptin 50 mg per day was the most commonly applied dose (77 %), and SU was co-administered in 77% of patients, biganide (BG) was 60%, and thiazolidinedione (TZD) was 21%. Doses of either sitagliptin or co-administered OHA had not been changed in all patients throughout the study period. Sixty patients (37%) had been obliged to discontinue α-glucosidase inhibitor (α-GI) at the commencement of sitagliptin because the co-administration of sitagliptin with α-GI had not been approved by the health insurance system in Japan until June in 2011. All analysis mentioned below were performed either in all patients or in separate groups of patients with or without the switching finally advocated the guideline for the use of sitagliptin on April in 2010 (http://www.jds.or.jp/jds_or_jp0/ uploads/photos/666.pdf). So far, there have been a few reports concerning efficacy and safety of sitagliptin for a long-term administration in Japan [7, 8] . In the present study, we searched glucose-lowering effect of sitagliptin in outpatients of our clinic for up to 6 months in relation to putative factors which may be concerned with its efficacy. It is of interest that there existed some patients whose hemoglobin A1c (HbA1c) had initially decreased and thereafter showed exacerbation to some extent during 6 months sitagliptin treatment, and characteristics of those patients were further evaluated.
Subjects and Methods

Patients
Type 2 diabetic outpatients who had been treated in Kurume University Hospital and other satellite hospitals or clinics were recruited, and those who had been prescribed sitagliptin since December in 2009 were selected as candidates in the present study. The diagnosis of diabetes was confirmed according to the criteria of the Japan Diabetes Society [16] or by medical history of diabetes. Patients who had been treated by SU or insulin with the cessation or cutting down the ini- The sum of points was used for the analysis below as the score for lifestyle assessment.
The HbA1c reduction for the initial 3 months was expressed as the ratio of the baseline HbA1c value instead of the absolute difference (⊿) after the initiation of sitagliptin, because ⊿HbA1c is considerably amplified in proportion to the baseline value of HbA1c itself [7] . The HbA1c reduction = [(HbA1c value after 3 months) -(baseline HbA1c value)] / (baseline HbA1c value).
Patients were classified into three groups according to the value of the HbA1c reduction for 3 months (Tables 2 and 3 ). Baseline characteristics and the from α-GI.
Protocol
Fasting (FPG) or post-prandial plasma glucose (PPG) levels, HbA1c (JDS [9] ) and body weight were measured before and every month after the initiation of sitagliptin. Although either FPG or PPG was measured in every patient according to the convenience of each patient, either PG had been consistently measured throughout 6 months. Consequently, FPG was measured in 52 patients and PPG in 112 patietns up to 3 months after the start of sitagliptin. PPG was measured 2 hours after they had eaten their usual breakfast. Plasma glucose levels were measured by glucose oxidase method, HbA1c levels were by HPLC method (Arkray Inc. Kyoto). At the initiation of sitagliptin, the evaluations of life-style were made according to the check list modified for the present study [10] as below. changes of blood glucose level and body weight were compared among these 3 groups to explore any factors to predict the efficacy of sitagliptin before initiation of this drug. Among patients belonging to 2 nd and 3 rd tertiles in whom sitagliptin brought a moderate and marked reduction of HbA1c for the first 3 months (109 patients), 11 patients were excluded from the second analysis after 6 months due to either lack of available data or quitting their regular examination to our clinic for the next 3 months. Consequently, 98 patients in 2 nd and 3 rd tertile after 3 months were further evaluated after 6 months with regard to the deterioration of HbA1c (relapsing). The relapsing of HbA1c was defined as the increase of HbA1c with more than half value of the reduction for initial 3 months or more than 0.4% between 3 and 6 months. Under this definition the relapsing was observed in 45 patients after 6 months, and baseline characteristics and the changes of body weight were again compared with those in 53 patients without the relapsing (Tables 4 and 5 ).
Statistical analysis
All tests were performed using SAS ver. 9.2 (SAS Institute Inc., USA) and all data were expressed as 
Results
Effects of sitagliptin on blood glucose and body weight after 3 months
Overall reduction of HbA1c by the treatment of sitagliptin was 0.8% (from 7.8±1.2% to 7.0±1.1%, P<0.0001) after 3 months, whilst no reduction or rather increase of HbA1c was observed in 30 patients (18%, Fig. 1 ). Although body weight did not change significantly during 3 months of sitagliptin treatment (from means±S.D. Student's paired t-test was used for the comparisons of values between before and after 3 months, and one-way repeated measures ANOVA among before, after 3 and 6 months. One-way ANOVA or Kruskal Wallis test (non-parametric data) was used for the comparison of 3 groups after 3 months. Student's unpaired t-test (parametric data) or MannWhitney U-test (non-parametric data) was used for the comparison of 2 groups after 6 months. Logistic regression analysis was further applied for the determination of independent baseline variables which contributes to relapsing of HbA1c after 6 months. chi-square test was used for the comparison of proportion among cant explanatory variables ( Table 6 ).
Safety of sitagliptin treatment
During 6-month treatment, no patient have experienced a severe hypoglycemic episode which needed someone's help. Mild and transient hypoglycemia occurred in 12 patients with the concomitant use of SU, in whom cutting down of SU was not necessary. No gastro-intestinal side effect occurred, or no abnormal biochemical data such as transaminase, creatinine, blood cell counting or electrolyte was reported.
Discussion
Major findings of the current study investigating efficacy and safety of sitagliptin in type 2 diabetic patients are described below. First, no serious adverse effect including severe hypoglycemia has been reported in our outpatients. Second, the overall reduction of HbA1c was 0.8% after both 3 and 6 months with no weight gain in all patients. Third, a modest number of patients did not respond sitagliptin treatment, while it was difficult to distinguish the efficacy before the initiation of treatment. Finally, there were a moderate number of patients in whom HbA1c had initially decreased and then relapsed to some extent after 6 months of sitagliptin treatment.
Sitagliptin has been expected to exert a glucose-dependent insulinotropic effect [3] and a modest inhibition of appetite [6] , thus effectively reduce HbA1c without an episode of hypoglycemia and weight gain which has been longstanding problems of OHA, especially SU. In clinical practice, however, severe hypoglycemic episodes have been reported in combination with SU treatment just after the release of this drug (between January and March in 2010), and JDS advocated the guideline for the use of sitagliptin on April in 2010 mentioned as above. We didn't experienced any 62.6±13.0 kg to 62.4±12.7 kg) in all patients, more than half of patients revealed weight gain to a greater or lesser extent (Fig. 1) .
Putative baseline characters which might have affected the degree of HbA1c reduction were examined among 3 groups classified by the HbA1c reduction. There were no significant differences in age, gender, duration of diabetes, initial BMI and the score for lifestyle assessment among 3 groups. The baseline HbA1c value was positively correlated to the HbA1c reduction in line with the previous report [7] . Neither types of co-administered OHA nor the switching from α-GI affected the reduction of HbA1c ( Table 2 ). The change of PG, especially ⊿PPG, after either 1 or 3 months was significantly and to the same extent related to the effect of sitagliptin on the HbA1c reduction, while ⊿body weight did not change among those 3 groups (Table 2) . Separately analyzed according to the switching from α-GI, the baseline HbA1c was also the sole predictor for the HbA1c reduction and ⊿PPG after either 1 or 3 months was related to the glucose lowering effect of sitagliptin in either group of patients (Table 3) .
Effects of sitagliptin on blood glucose and body weight after 6 months
Overall change of HbA1c in 98 patients during 6 months were 7.9±1.1% before treatment, 6.8±0.9% after 3 months and 6.9±0.9% after 6 months, respectively (P<0.0001). The change of HbA1c in 53 patients without the relapsing was from the baseline value of 8.1±1.2% to 7.0±1.0% after 3 months and 6.7±0.9% after 6 months, and that in 45 patients with relapsing was from 7.7±1.0% to 6.5±0.7% and 7.1±0.8%, respectively. Baseline characters which might have affected relapsing of HbA1c were further compared between those two groups of patients. In patients with the relapsing, the duration of diabetes was longer, ⊿body weight after 6 months was greater, the score for lifestyle assessment was lower, and more cases switched from α-GI existed compared to those in patients without relapsing (Table 4) . If patients were confined to the cases switched from α-GI, a significant weight gain after 6 months was observed solely in relapsing cases. Conversely, a significantly lower scores for life-style assessment was noted in relapsing patients belonged to the group without the switching from α-GI (Table 5) . After multivariate analysis of the relapsing as an outcome variable, the switching from α-GI and the lower score for life-style assessment were selected as signifi- concentrations were reported in non-diabetic men [15] . As α-GI is expected to suppress appetite probably due to the enhancement of GLP-1 secretion [14] , switching from α-GI to sitagliptin might have produced weight gain observed in our patients after 6 months and then contributed to the relapsing of HbA1c. From this point of view it is interesting that a significant weight gain was observed solely in relapsing cases if patients were restricted to those switched from α-GI. On the other hand, relapsing patients had a significantly lower score for life-style assessment, especially in cases without switching from α-GI, implying that the persistent reinforcement of education for diet and exercise has been emphasized again same as other OHAs, especially in patients treated by sitagliptin for more than 3 months.
The limitation of the current study is the failure of measurement for endogenous insulin secretion such as plasma c-peptide concentration, thus the efficacy of sitagliptin could not be discussed from the aspect of insulin secretion capacity. Because most patients had been followed up by endocrinologists who had specialized in diabetes management before enrollment, the selection bias could not be fully excluded. In the present study, switching from other OHAs to sitagliptin was only the case in the initial α-GI treatment because of the obligation of health insurance in Japan. It is possible that the cessation or cutting down of co-administered any OHAs could cause relapsing of HbA1c besides α-GI. This is a cross-sectional observation study which contains neither a control arm nor prospective strategic interventions. Future randomized controlled studies with larger subjects are awaited to elucidate these unsolved questions.
While sitagliptin is a newly developed alternative for the treatment of type 2 diabetic patients and its efficacy has been demonstrated so far including this study, there still remains a possibility of unknown adverse events [16] and the positioning as a glucose-lowering agent has not been well validated [17] . Cautious attitude for the administration of sitagliptin is further essential in clinical practice, keeping the facts in mind that the individual variation of efficacy and the possibility of relapsing exist apart from hypoglycemia and weight gain.
